


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



in which

R is C(=NH)-NH₂, which may also be monosubstituted by OH, OCOOA, OCOO(CH₂)_nN(A)₂, OCOO(CH₂)_m-Het, COO(CH₂)_nN(A)₂, COO(CH₂)_m-Het, CO-C(A)₂-R⁴, COOA, COSA, COOAr or COOAr', or is CH₂NH₂,



R¹ is unbranched or branched alkyl having 1-20 carbon atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or also 1-7 H atoms may be replaced by F,
or is Ar or Ar',

R² is phenyl which is monosubstituted by S(O)_pA, S(O)_pNHA, CF₃, COOA or CH₂NHA,

R³ is H or Hal,

R⁴ is -CH₂Hal₃, O(C=O)A or

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A, OH, OA, NH₂, NHA, NA₂, NO₂, CF₃, CN, Hal, COA, NHCOA, COOA, CONH₂, CONHA, CONA₂, S(O)_pA, S(O)_pNH₂, S(O)_pNHA or S(O)_pNA₂,

Ar' is -(CH₂)_n-Ar,

A is H, or unbranched, branched or cyclic alkyl having 1-20 carbon atoms,
Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic
radical having from 1 to 4 N, O and/or S atoms, which may be
unsubstituted or monosubstituted or disubstituted by A,
Hal is F, Cl, Br or I,
n is 1, 2, 3, 4, 5 or 6,
m is 1, 2, 3, 4, 5 or 6,
p is 0, 1 or 2,
and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1, in which
R is amidino, which may also be substituted by OH, or is CH₂NH₂,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
3. (Original) Compounds according to Claim 1, in which
R¹ is phenyl, benzyl or alkyl having 1, 2, 3, 4, 5, 6 or 7 carbon atoms,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.
4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~ Claim 1, in
which R³ is H or F, and pharmaceutically usable derivatives, solvates and
stereoisomers thereof, including mixtures thereof in all ratios.
5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~ Claim 1, in
which R² is a phenyl radical which is monosubstituted by alkylsulfonyl or
aminosulfonyl, and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~ Claim 1, in
which R² is a phenyl radical which is monosubstituted by methylsulfonyl or
aminosulfonyl, and pharmaceutically usable derivatives, solvates and stereoisomers
thereof, including mixtures thereof in all ratios.
7. (Original) Compounds according to Claim 1, selected from the group consisting of

1-(3-N-hydroxyamidinophenyl)-4-(3-fluoro-2'-methylsulfonylbiphenyl-4-yl)-1-

phenylsemicarbazide,
1-(3-amidinophenyl)-4-(3-fluoro-2'-methylsulfonylbiphenyl-4-yl)-1-phenylsemicarbazide,
1-(3-aminomethylphenyl)-4-(3-fluoro-2'-methylsulfonylbiphenyl-4-yl)-1-phenylsemicarbazide,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-7~~ Claim 1 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that
 - a) they are liberated from one of their functional derivatives by treatment with a solvolysing and/or hydrogenolysing agent by
 - i) liberating an amidino group from its oxadiazole derivative or oxazolidinone derivative by hydrogenolysis or solvolysis,
 - ii) replacing a conventional amino-protecting group with hydrogen by treatment with a solvolysing or hydrogenolysing agent or liberating an amino group protected by a conventional protecting group,
 - b) a radical R¹, R² and/or Y is converted into another radical R¹, R² and/or Y by
 - i) converting a cyano group into an amidino group,
 - ii) reducing an amide group to an aminoalkyl group,
 - iii) reducing a cyano group to an aminoalkyl group,

and/or

a base or acid of the formula I is converted into one of its salts.

9. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 7~~ Claim 1 as inhibitors of coagulation factor Xa.
10. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 7~~ Claim 1 as inhibitors of coagulation factor VIIa.
11. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 7~~ Claim 1 and/or pharmaceutically usable

- derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
12. (Currently Amended) Medicaments comprising at least one compound of the formula I according to one or more of ~~Claims 1 to 7~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
 13. (Currently Amended) Use of compounds according to ~~Claims 1 to 7~~ Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
 14. (Currently Amended) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 7~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of a further medicament active ingredient.
 15. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 7~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.